209 related articles for article (PubMed ID: 8101692)
21. A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
Yamashita T; Nakasu Y; Mizutani H; Sumitani K
J Cardiol; 2019 Nov; 74(5):418-425. PubMed ID: 31255463
[TBL] [Abstract][Full Text] [Related]
22. Left ventricular performance during acute rate control in atrial fibrillation: the importance of heart rate and agent used.
Pinter A; Dorian P; Paquette M; Ng A; Burns M; Spanu I; Freeman M; Korley V; Newman D
J Cardiovasc Pharmacol Ther; 2003 Mar; 8(1):17-24. PubMed ID: 12652326
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter.
Ellenbogen KA; Dias VC; Cardello FP; Strauss WE; Simonton CA; Pollak SJ; Wood MA; Stambler BS
Am J Cardiol; 1995 Jan; 75(1):45-9. PubMed ID: 7801862
[TBL] [Abstract][Full Text] [Related]
24. Dilemmas in the acute pharmacologic treatment of uncontrolled atrial fibrillation.
Elam K; Bolar-Softich KL
Am J Emerg Med; 1997 Jul; 15(4):418-9. PubMed ID: 9217541
[TBL] [Abstract][Full Text] [Related]
25. Intravenous esmolol is well tolerated in elderly patients with heart failure in the early phase of non-ST elevation myocardial infarction.
Koutouzis M; Nikolidakis S; Grigoriadis A; Koutsogeorgis D; Kyriakides ZS
Drugs Aging; 2006; 23(8):673-80. PubMed ID: 16964989
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials.
Perrett M; Gohil N; Tica O; Bunting KV; Kotecha D
Clin Res Cardiol; 2024 Jun; 113(6):831-841. PubMed ID: 37658166
[TBL] [Abstract][Full Text] [Related]
27. Atrial fibrillation and flutter. Immediate control and conversion with intravenously administered verapamil.
Tommaso C; McDonough T; Parker M; Talano JV
Arch Intern Med; 1983 May; 143(5):877-81. PubMed ID: 6679229
[TBL] [Abstract][Full Text] [Related]
28. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
Joseph AP; Ward MR
Ann Emerg Med; 2000 Jul; 36(1):1-9. PubMed ID: 10874228
[TBL] [Abstract][Full Text] [Related]
29. Heart rate outcomes with concomitant parenteral calcium channel blockers and beta blockers in rapid atrial fibrillation or flutter.
Alowais SA; Hayes BD; Wilcox SR; Le J; Koehl JL; Fuh L
Am J Emerg Med; 2021 Jun; 44():407-410. PubMed ID: 32448773
[TBL] [Abstract][Full Text] [Related]
30. Intravenous amiodarone used alone or in combination with digoxin for life-threatening supraventricular tachyarrhythmia in neonates and small infants.
Dilber E; Mutlu M; Dilber B; Aslan Y; Gedik Y; Celiker A
Pediatr Emerg Care; 2010 Feb; 26(2):82-4. PubMed ID: 20093999
[TBL] [Abstract][Full Text] [Related]
31. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).
Nagai R; Kinugawa K; Inoue H; Atarashi H; Seino Y; Yamashita T; Shimizu W; Aiba T; Kitakaze M; Sakamoto A; Ikeda T; Imai Y; Daimon T; Fujino K; Nagano T; Okamura T; Hori M;
Circ J; 2013; 77(4):908-16. PubMed ID: 23502991
[TBL] [Abstract][Full Text] [Related]
32. Esmolol versus diltiazem in atrial fibrillation following coronary artery bypass graft surgery.
Hilleman DE; Reyes AP; Mooss AN; Packard KA
Curr Med Res Opin; 2003; 19(5):376-82. PubMed ID: 13678474
[TBL] [Abstract][Full Text] [Related]
33. Beta-blocking therapy in atrial and ventricular tachyarrhythmias: experience with nadolol.
Coumel P; Escoubet B; Attuel P
Am Heart J; 1984 Oct; 108(4 Pt 2):1098-108. PubMed ID: 6148870
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group.
Salerno DM; Dias VC; Kleiger RE; Tschida VH; Sung RJ; Sami M; Giorgi LV
Am J Cardiol; 1989 May; 63(15):1046-51. PubMed ID: 2650517
[TBL] [Abstract][Full Text] [Related]
35. Antiarrhythmic activity of esmolol (ASL-8052)--a novel ultra-short acting beta-adrenoreceptor blocking agent.
Klein G; Wirtzfeld A; Alt E; Steck J; Saunders R; Hulse J; Kartzinel R; Lee R; Laddu AR
Int J Clin Pharmacol Ther Toxicol; 1984 Feb; 22(2):112-7. PubMed ID: 6142005
[TBL] [Abstract][Full Text] [Related]
36. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure.
Goldenberg IF; Lewis WR; Dias VC; Heywood JT; Pedersen WR
Am J Cardiol; 1994 Nov; 74(9):884-9. PubMed ID: 7977118
[TBL] [Abstract][Full Text] [Related]
37. Acute ventricular rate control in atrial fibrillation and atrial flutter.
Khan IA; Nair CK; Singh N; Gowda RM; Nair RC
Int J Cardiol; 2004 Oct; 97(1):7-13. PubMed ID: 15336799
[TBL] [Abstract][Full Text] [Related]
38. Antiadrenergic therapy in the control of atrial fibrillation.
Naccarelli GV
J Cardiovasc Pharmacol Ther; 2005 Jun; 10 Suppl 1():S33-43. PubMed ID: 15965571
[TBL] [Abstract][Full Text] [Related]
39. Symptomatic and hemodynamic recovery following dobutamine stress echo: benefit of low-dose esmolol administration.
Abdullah EE; Pollick C
Int J Card Imaging; 1997 Feb; 13(1):53-7. PubMed ID: 9080239
[TBL] [Abstract][Full Text] [Related]
40. Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. The Esmolol Research Group.
Am Heart J; 1986 Sep; 112(3):498-505. PubMed ID: 2875641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
